Phenobarbital

Republic of the Philippines
CEBU NORMAL UNIVERSITY

Osmeña Blvd., Cebu City, 6000, Philippines
College of Nursing
Telephone No.: (+63 32) 254
4837 Email: cn@cnu.edu.ph
Website: www.cnu.edu.ph
DRUG STUDY
Patient’s Initials: P.R. Date of Admission: March 13, 2022 Diagnosis: Seizure Disorder
Age: 48 years old Height: 155 cm Weight: 65 kgs. Clinical Intervention: for EEG for seizure recurrence
Sex: Female Ward: Medical Bed No.:1 Name of Physician: Dr. Bilocura
Drug Information Classification Mechanism of Action Indication Contraindications Side Effects Nursing Responsibilities
Generic Name: Pharmacologic Pharmacodynamics or Mechanism of General Indication/s: Contraindicated in: (per system preferably) Before Drug Administration:
Phenobarbital Classification: Action:  To treat seizures  Hepatic disease  Check the doctor's order.
Barbiturate Inhibits ascending conduction of  To treat status  history of addiction to CNS: Anxiety, depression,  Perform a physical
Trade Name: impulses in the reticular formation, epilepticus hypnotics or sedatives dizziness, drowsiness, assessment and assess
Ancef Therapeutic which controls CNS arousal to  To provide short-term  hypersensitivity to headache, irritability, lethargy, vital signs.
Classification: produce drowsiness, hypnosis, and treatment of phenobarbital, other mood changes, paradoxical  Educate patient about the
Minimum Dose: Anticonvulsant, sedation. Phenobarbital also insomnia barbiturates, or their stimulation, sedation, vertigo drug, its effect, and
60 mg daily as a sedative-hypnotic decreases the spread of seizure  To treat febrile components common side effects.
single dose or in activity in cortex, thalamus, and convulsions in young  nephritis CV: Hypotension, sinus  Because drug can cause
divided doses Pregnancy Category limbic system. It promotes an children  porphyria bradycardia respiratory depression,
D increased threshold for electrical To provide daytime  severe respiratory assess respiratory rate
Maximum Dose: stimulation in the motor cortex, which sedation disease with airway EENT: Miosis, ptosis and depth before use.
250 mg daily as a Controlled may contribute to its anticonvulsant
 To provide obstruction or dyspnea
single dose or in Substance Schedule properties. Effective as a sedative, preoperative GI: Constipation, diarrhea, During Drug Administration:
divided doses IV hypnotic, and an anticonvulsant with sedation Cautious Use: nausea, vomiting  Ensure right patient, right
no analgesic effect. drug, right dose, right
 Impaired liver, kidney,
Patient’s Dose: Patient’s Indication: GU: Decreased libido, time, and right route.
cardiac, or respiratory
90 mg/tab, 2 tablets Pharmacokinetics: Maintenance medication impotence, sexual dysfunction  Give crushed and mixed
function
daily (maximum: 3 Absorption: 70–90% slowly from GI for patient’s generalized with a fluid or with food if
 sleep apnea
tablets) tract. seizure episodes MS: Arthralgia, bone patient cannot swallow
 COPD tenderness
 history of allergies pill. Do not permit patient
Route: Peak: 8–12 h PO to swallow dry crushed
Certification Date: 1 February 2021

Recertification due date: 24 January 2024
SDF-CON-304-071-00
For verification of the certificate please
access www.gcl-intl.com (Certification Page 1 of 4
check and type the registration number)
Registration No. 52Q18778

College of Nursing
PO  patients with fever RESP: Bronchospasm, drug.

Duration: 4–6 h IV.  hyperthyroidism respiratory depression
Frequency:  diabetes mellitus or
Before bedtime Distribution: 20–45% protein bound; severe anemia SKIN: Dermatitis, After Drug Administration:
crosses placenta; enters breast milk.  seizure disorders photosensitivity, rash,  Caution patient about
Availability/Form: urticaria possible drowsiness and
Tablet; capsule; Metabolism: In liver (CYP2C19). Interactions: reduced alertness. Advise
liquid; solution for DRUGS Other: physical and her to avoid potentially
injection Elimination: In urine.  acetaminophen: psychological dependence hazardous activities until
Decreased drug’s CNS effects are
Content: Half-Life: 2–6 days acetaminophen known.
Each Phenobarbital effectiveness with long-  Maintain adequate dietary
Tablet, USP contains term phenobarbital folate intake: Fresh
15 mg, 30 mg, 60 mg therapy vegetables (especially
or 100 mg of  CNS depressants: green leafy), fresh fruits,
phenobarbital, USP. Additive CNS whole grains, liver. Long-
Inactive ingredients depression term therapy may result in
are as follows: 15 mg, ACTIVITIES nutritional folate (B9)
30 and 60 mg: deficiency. A supplement
 alcohol use: Additive
Calcium Stearate, of folic acid may be
CNS depression
Colloidal Silicon prescribed.
Dioxide, Corn Starch,  Be aware that drug may
and Microcrystalline cause physical and
Cellulose. psychological
dependence.
 Expect that
phenobarbital’s CNS
effects may exacerbate
major depression, suicidal

SDF-CON-304-071-00

College of Nursing
tendencies, or other
mental disorders.
 Adhere to drug regimen
(i.e., do not change
intervals between doses
or increase or decrease
doses) without contacting
prescriber.
 Do not stop taking drug
abruptly because of
danger of withdrawal
symptoms (8–12 h after
last dose), which can be
fatal.
 Urge patient to avoid
alcohol during therapy.
 Report to prescriber the
onset of fever, sore throat
or mouth, malaise, easy
bruising or bleeding,
petechiae, jaundice, rash
when on prolonged
therapy.
References:
Jones & Bartlett Learning. (2021). 2022 Nurse’s Drug Handbook (21st ed.). Jones & Bartlett Learning.

SDF-CON-304-071-00

College of Nursing
Karch, Amy. 2011. 2011 Lippincott’s Nursing Drug Guide pp 748-749
Wilkes, G. M., & Barton-Burke, M. (2019). 2020-2021 Oncology Nursing Drug Handbook (23rd ed.). Jones & Bartlett Learning.
Wilkins, W. L. (2021). Nursing2022 Drug Handbook (Nursing Drug Handbook) (Forty-Second, North American ed.). LWW.

SDF-CON-304-071-00

CEBu NORMAL UNIvERSITy
College of Nursing
PRODUCT ASSESSMENT RUBRICS FOR DRUG STUDY
Student Name: Rosales, Gwyn A. Year/Section: BSN- 4B Date: February 28, 2022 Score: /30
Directions: Please select the appropriate rating using the following descriptions.
Element Very Satisfactory Satisfactory Needs Comments

Improvement
Drug ☐ Accurately presented all of the patient and drug ☐ Accurately presented most of the patient and ☐ Accurately presented some of the patient and drug
Information information (name [brand & generic], dosage [patient’s drug information related to the case. 1 missing information related to the case. 2 or more missing
(10%) dose; min. & max], frequency, route, availability, information or error noted. [2] information or errors noted. [1]
contents) related to the case. [3]
Classificatio ☐ Accurately presented the classification ☐ Accurately presented the classification related to ☐ Inaccurately presented the classification related to
n (10%) (therapeutic and pharmacologic) related to the drug. the drug but with 1 irrelevant information or error the drug. Classification is not relevant to the drug. [1]
[3] noted. [2]
☐ Accurately presented the indication/s (general & ☐ Accurately presented the indication/s related to ☐ Inaccurately presented the indication/s related to the
Indication (10%)
patient- specific) related to the drug. [3] the drug but with 1 irrelevant information or error drug. Indication is not relevant to the drug. [1]
noted. [2]
Mechanism ☐ Accurately presented the mechanism of ☐ Accurately presented the mechanism of action of ☐ Inaccurately presented the mechanism of action of
of Action action (pharmacokinetics, pharmacodynamics) of the drug but with 1 irrelevant information or error the drug. Mechanism of action is not relevant to the
(10%)
the drug. [3] noted. [2] drug. [1]
☐ Accurately presented all of the common ☐ Accurately presented most of the common ☐ Accurately presented some of the common
Contraindication
contraindications related to the drug. [3] contraindications related to the drug. 1 missing contraindications related to the drug. 2 or more missing
(10%)
information or error noted. [2] information or errors noted. [1]
Side ☐ Accurately presented all of the common side effects ☐ Accurately presented most of the common side ☐ Accurately presented some of the common side
Effects related to the drug. [3] effects related to the drug. 1-2 missing information or effects related to the drug. 3 or more missing
(10%)
errors noted. [2] information or errors noted. [1]
Nursing ☐ Accurately presented all of the common nursing ☐ Accurately presented most of the common ☐ Accurately presented some of the common

SDF-CON-304-071-00

CEBu NORMAL UNIvERSITy
College of Nursing
Responsibilitie responsibilities (before, during, and after) related to the nursing nursing
s (30%) drug. [9] responsibilities related to the drug. 1-2 missing responsibilities related to the drug. 3 or more missing
information or errors noted. [7] information or errors noted. [3]
☐ Presented at least 2 sources that are updated ☐ Presented only one source that is updated (within ☐ No source was presented. Sources are not updated
Reference
s (10%) (within 5 years), relevant, and credible. [3] 5 years), relevant, and credible. Other sources are (more than 5 years), relevant, and credible. [1]
not updated, credible or relevant. [2]
Sub-score = = =
Evaluated by:
SUET ROSE CARRILLO
Signature over Printed Name of Clinical Instructor

SDF-CON-304-071-00

Phenobarbital

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Phenobarbital

Uploaded by

Copyright:

Available Formats

Republic of the Philippines

CEBU NORMAL UNIVERSITY

Certification Date: 1 February 2021

Registration No. 52Q18778

PO  patients with fever RESP: Bronchospasm, drug.

Certification Date: 1 February 2021

Registration No. 52Q18778

Certification Date: 1 February 2021

Registration No. 52Q18778

Karch, Amy. 2011. 2011 Lippincott’s Nursing Drug Guide pp 748-749

Certification Date: 1 February 2021

Registration No. 52Q18778

PRODUCT ASSESSMENT RUBRICS FOR DRUG STUDY

Element Very Satisfactory Satisfactory Needs Comments

Certification Date: 1 February 2021

Registration No. 52Q18778

Signature over Printed Name of Clinical Instructor

Certification Date: 1 February 2021

Registration No. 52Q18778

You might also like